Abivax abstract on obefazimod phase 2b results selected for moderated poster presentation at UEG Week 2022
Obefazimod (ABX464) interim 48-week safety and efficacy analysis from the ongoing phase 2b maintenance study in moderate-to-severe ulcerative colitis (UC) selected by UEG as "one of the best abstracts" and eligible for an oral presentation at a moderated poster session
Principal investigator Prof. Sverine Vermeire, M.D., Ph.D., to present Abivax's poster on October 10, 2022, at 11:54 a.m.- 12:00 (noon) CEST (5:54 a.m.-6:00 a.m. EST)
PARIS, FRANCE / ACCESSWIRE / September 27, 2022 / Abivax SA (Euronext Paris:FR0012333284 - ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces today that its abstract on the obefazimod interim 48-week safety and efficacy analysis from the ongoing open-label phase 2b maintenance study in moderate to severe ulcerative colitis (UC) has been selected as "one of the best abstracts" for UEG (United European Gastroenterology) Week 2022. The corresponding poster is therefore eligible for an oral presentation during a moderated poster session, in addition to the poster exhibition in the Science Lounge and the Virtual Poster Exhibition.
UEG Week 2022 takes place in Vienna, Austria, from October 8-11, 2022, and is one of the world's leading congresses focused on gastrointestinal diseases, such as Inflammatory Bowel Diseases (IBD).
The poster will be presented by Prof. Sverine Vermeire, M.D., Ph.D., the study's principal investigator. Participants will have the opportunity to ask questions after the presentation.
Abstract:
#AS-UEG-2022-01013
Session:
Clinical trials in IBD - Moderated Poster Session 3 (MP250)
Talk:
ABX464 (obefazimod) in patients with moderate-to-severe ulcerative colitis: An interim 48-week safety and efficacy analysis from an ongoing 96-week open-label maintenance phase 2b study
Story continues
Time:
October 10, 2022 - at 11:54 a.m.-12:00 (noon) CEST (5:54-6:00 a.m. EST)
Presenter:
Prof. Sverine Vermeire, M.D., Ph.D., Head of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator of the obefazimod phase 2a and phase 2b clinical studies, as well as of the obefazimod global phase 3 clinical program in UC
The moderated poster sessions at this year's UEG Week will neither be recorded nor streamed online. Only registered UEG Week participants can attend the poster session at the conference venue.
In addition to the selection of the abstract by UEG, the obefazimod phase 2b study results in UC have recently been scientifically validated with the publication of an article in the peer-reviewed journal "The Lancet Gastroenterology & Hepatology".[1] The title of the article is "ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension".[2]
Obefazimod global pivotal phase 3 clinical program in UC
Following the promising results of the phase 2a and phase 2b clinical induction and maintenance studies with obefazimod in UC, Abivax launched a global pivotal phase 3 clinical program with its drug candidate in moderate to severe ulcerative colitis patients.
1,200 UC patients across 36 countries will take part in the pivotal phase 3 program that consists of two induction studies and a single subsequent maintenance study (ABTECT-1 (ABX464-105) and ABTECT-2 (ABX464-106) induction trials and ABTECT maintenance trial (ABX464-107)). These three pivotal studies are all randomized, double-blind, and placebo controlled, using independent, blinded review of the videotaped endoscopies. The primary efficacy endpoint assessed at week 8 (induction) and at week 44 (maintenance) will be clinical remission according to the modified Mayo Score, as required by FDA.[3]
Currently, more than 430 study sites, out of the targeted 600 sites, have already been qualified to take part in the phase 3 trials.
In August, Abivax received approval from the central US Institutional Review Board (IRB) for the protocols of the phase 3 induction studies. This allows the initiation of enrollment of patients into the two studies in UC in the US. A first patient is anticipated to be included at the end of September 2022.
*****
About Abivax (www.abivax.com)
Abivax, a phase 3 clinical stage biotechnology company, is developing novel therapies that modulate the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 - Mnmo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, obefazimod (ABX464) to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at http://www.abivax.com. Follow us on Twitter @ABIVAX_.
Contacts
Abivax Communications Regina Jehle regina.jehle@abivax.com +33 6 24 50 69 63
Investors LifeSci Advisors Ligia Vela-Reid lvela-reid@lifesciadvisors.com +44 7413 825310
Press Relations & Investors Europe MC Services AG Anne Hennecke anne.hennecke@mc-services.eu +49 211 529 252 22
Public Relations France Actifin Ghislaine Gasparetto ggasparetto@actifin.fr +33 6 21 10 49 24
Public Relations France Primatice Thomas Roborel de Climens thomasdeclimens@primatice.com +33 6 78 12 97 95
Public Relations USA Rooney Partners LLC Jeanene Timberlake jtimberlake@rooneypartners.com +1 646 770 8858
DISCLAIMER
This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although Abivax' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorit des Marchs Financiers pursuant to its legal obligations including its registration document (Document d'Enregistrement Universel). These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.
[1] "The Lancet Gastroenterology & Hepatology" has an Impact Factor of 45 (2021 Journal Citation Reports , Clarivate 2022).
[2] Severine Vermeire et al.: ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48-week, open-label extension, Lancet Gastroenterol Hepatol, published online on Sept. 5, 2022.
[3] Modified Mayo Score refers to stool frequency, rectal bleeding and endoscopy sub score.
SOURCE: ABIVAX
View source version on accesswire.com: https://www.accesswire.com/717645/ABIVAX-Abstract-On-Obefazimod-Phase-2B-Results-Selected-For-Moderated-Poster-Presentation-At-UEG-Week-2022
See more here:
ABIVAX Abstract On Obefazimod Phase 2B Results Selected For Moderated Poster Presentation At UEG Week 2022 - Yahoo Finance
- GW Pharma Reports Preliminary Topline Results Of Ulcerative Colitis Trial - October 15th, 2014 [October 15th, 2014]
- Ulcerative Colitis: Facts on Symptoms, Treatment and Diet - October 15th, 2014 [October 15th, 2014]
- Ulcerative Colitis - National Digestive Diseases ... - October 15th, 2014 [October 15th, 2014]
- CCFA: What is Ulcerative Colitis | Inflammatory Bowel Disease - October 15th, 2014 [October 15th, 2014]
- Ulcerative Colitis: Get Facts on Symptoms and Diet - October 15th, 2014 [October 15th, 2014]
- Ulcerative colitis - Wikipedia, the free encyclopedia - October 15th, 2014 [October 15th, 2014]
- Ulcerative Colitis Testimonial - Video - October 15th, 2014 [October 15th, 2014]
- My Fight With Ulcerative Colitis - Video - October 15th, 2014 [October 15th, 2014]
- Diet in Ulcerative Colitis - Best and Worst Foods - Video - October 15th, 2014 [October 15th, 2014]
- Why Ulcerative Colitis is (Literally) a Pain in the Butt - Video - October 15th, 2014 [October 15th, 2014]
- My Journey= Ulcerative Colitis Proctitis PART 1 - Video - October 15th, 2014 [October 15th, 2014]
- Top 15 Ways to Cure Ulcerative Colitis Naturally - Diet & Home Remedies - Video - October 15th, 2014 [October 15th, 2014]
- Updates in Ulcerative Colitis & Crohn's disease - October 17th, 2014 [October 17th, 2014]
- Ulcerative colitis Symptoms - Diseases and Conditions ... - October 17th, 2014 [October 17th, 2014]
- Dr. Morse Explains Ulcerative Colitis and Intestinal Conditions - Video - October 20th, 2014 [October 20th, 2014]
- Depression Stress Anxiety IBS Colitis Arthritis Treatment Allergy Testing Reiki Healing Scotland W - Video - October 20th, 2014 [October 20th, 2014]
- Taylor Healing process - Video - October 20th, 2014 [October 20th, 2014]
- Treating Pediatric Inflammatory Bowel Disease - Video - October 20th, 2014 [October 20th, 2014]
- Take Steps Walk for Crohn's and Colitis - Video - October 21st, 2014 [October 21st, 2014]
- Ulcerative Colitis & Me - Video - October 21st, 2014 [October 21st, 2014]
- Ferring Pharmaceuticals: CORTIMENT MMX, a new treatment for ulcerative colitis, receives European approval - October 22nd, 2014 [October 22nd, 2014]
- Sleep duration affects risk for ulcerative colitis - October 22nd, 2014 [October 22nd, 2014]
- My Journey= Ulcerative Colitis Proctitis PART#3 - Video - October 23rd, 2014 [October 23rd, 2014]
- Added benefit of vedolizumab is not proven - October 24th, 2014 [October 24th, 2014]
- My Journey= Ulcerative Colitis Proctitis PART#2 - Video - October 24th, 2014 [October 24th, 2014]
- Why Food Network Star Sunny Anderson Can't Eat Vegetables - October 24th, 2014 [October 24th, 2014]
- New compounds reduce debilitating inflammation - October 26th, 2014 [October 26th, 2014]
- Sleep Duration Linked to Ulcerative Colitis Risk in Study - October 27th, 2014 [October 27th, 2014]
- Ulcerative colitis: MedlinePlus Medical Encyclopedia - October 27th, 2014 [October 27th, 2014]
- Ulcerative Colitis - American Society of Colon and Rectal ... - October 27th, 2014 [October 27th, 2014]
- NHS Ulcerative Colitis - NHS Choices - Your health, your ... - October 27th, 2014 [October 27th, 2014]
- Ulcerative Colitis - October 27th, 2014 [October 27th, 2014]
- How to heal intestines | Ulcerative Colitis | SCD Lifestyle - Video - October 27th, 2014 [October 27th, 2014]
- Ulcerative Colitis - Causes, Symptoms, Diet & Herbal Remedies in Punjabi - Video - October 27th, 2014 [October 27th, 2014]
- Receptos: good results for ulcerative colitis drug - October 29th, 2014 [October 29th, 2014]
- Should I Drink Alcohol if I Have Crohn's Disease or Ulcerative Colitis - Video - October 29th, 2014 [October 29th, 2014]
- New clinical trial data: Multiple sclerosis drug candidate also shows promise for ulcerative colitis - October 30th, 2014 [October 30th, 2014]
- TSRI's MS Drug Also Shows Promise In Ulcerative Colitis - November 1st, 2014 [November 1st, 2014]
- Justin Mirigliani repping 260lbs on the Bench! Never Surrender! Fighting Ulcerative Colitis! - Video - November 1st, 2014 [November 1st, 2014]
- Managing Ulcerative Colitis Naturally: Outlook & Perspective - Video - November 1st, 2014 [November 1st, 2014]
- My Ulcerative Colitis Diet - Video - November 1st, 2014 [November 1st, 2014]
- Healing my Ulcerative Colitis - Video - November 2nd, 2014 [November 2nd, 2014]
- Peoria Connections Interview - Successes with autoimmune disease, ADHD, ulcerative colitis - Video - November 2nd, 2014 [November 2nd, 2014]
- Crohns Disease & Ulcerative Colitis The Diagnosing Difficulties - Video - November 2nd, 2014 [November 2nd, 2014]
- My Ulcerative Colitis Story - Video - November 3rd, 2014 [November 3rd, 2014]
- Pudge Rodriguez will be special guest at Crohns and Colitis Foundation dinner - November 4th, 2014 [November 4th, 2014]
- Diagnosing Crohns Disease & Ulcerative Colitis - Video - November 4th, 2014 [November 4th, 2014]
- Natural Treatment for Ulcerative Colitis with Causes and Symptoms - Video - November 5th, 2014 [November 5th, 2014]
- Acute Severe Ulcerative Colitis - Video - November 5th, 2014 [November 5th, 2014]
- CME Outfitters and USF Health to Host Medical Symposium in Conjunction with the 2014 Advances in IBD Crohns & Colitis ... - November 7th, 2014 [November 7th, 2014]
- How sleep affects my Ulcerative Colitis Symptoms - Video - November 7th, 2014 [November 7th, 2014]
- Healing my Ulcerative Colitis Webcam video from November 4, 2014 05:49 PM - Video - November 7th, 2014 [November 7th, 2014]
- Managing Extra-Intestinal Manifestations of Crohn's Disease & Ulcerative Colitis - Video - November 7th, 2014 [November 7th, 2014]
- Causes and Treatment of Crohns Disease and Ulcerative Colitis - Video - November 8th, 2014 [November 8th, 2014]
- How to stop the Cause of IBS, Crohn's and Ulcerative Colitis - Video - November 8th, 2014 [November 8th, 2014]
- Introduction to Ulcerative Colitis - Video - November 8th, 2014 [November 8th, 2014]
- Ulcerative Colitis Dr Tehsina0 - Video - November 8th, 2014 [November 8th, 2014]
- Taking Steps Against Crohn's and Colitis - November 9th, 2014 [November 9th, 2014]
- How To Make Chicken 3 Ways + Gut Healing Bone Broth - by Thyroid Loving Care - Video - November 10th, 2014 [November 10th, 2014]
- Ileal Pouch - Anal Anastomosis in Chronic Ulcerative Colitis - Video - November 10th, 2014 [November 10th, 2014]
- Vlog #1 - November 10 2014 - Video - November 11th, 2014 [November 11th, 2014]
- Ulcerative Colitis Patient Success Story - Video - November 11th, 2014 [November 11th, 2014]
- How to Recover from Ulcerative Colitis - Video - November 12th, 2014 [November 12th, 2014]
- Vlog #2 - November 11, 2014 - Living with Ulcerative Colitis - Video - November 13th, 2014 [November 13th, 2014]
- How IBD (Crohn's Disease and Ulcerative Colitis) Affects Mental Health - Video - November 15th, 2014 [November 15th, 2014]
- Ulcerative Colitis Got Me Down - Video - November 15th, 2014 [November 15th, 2014]
- Surgeon Spotlight: Dr. Amit Merchea - Chronic Ulcerative Colitis - Video - November 16th, 2014 [November 16th, 2014]
- Ulcerative Colitis Proctitis: Doctor Update, Medications - Video - November 16th, 2014 [November 16th, 2014]
- Ulcerative Colitis Got You Down Too? - Video - November 16th, 2014 [November 16th, 2014]
- Management of ulcerative colitis - Wikipedia, the free ... - November 17th, 2014 [November 17th, 2014]
- IBD Support Group: Crohn's Disease and Ulcerative Colitis - November 17th, 2014 [November 17th, 2014]
- Crohn's Disease, Ulcerative Colitis and the Team Challenge endurance training program - Video - November 17th, 2014 [November 17th, 2014]
- Let's CRUSH Ulcerative Colitis LIke a Coke Can - Video - November 19th, 2014 [November 19th, 2014]
- 21 Weeks Pregnant Update! - Ultrasound & Ulcerative Colitis - Video - November 20th, 2014 [November 20th, 2014]
- Healing my Ulcerative Colitis Webcam video from November 17, 2014 02:48 PM - Video - November 20th, 2014 [November 20th, 2014]
- Is Crohns Disease or Ulcerative Colitis Hereditary? - Video - November 22nd, 2014 [November 22nd, 2014]
- Celebrity chef Sunny Anderson on living with irritable bowel disease - November 23rd, 2014 [November 23rd, 2014]
- 13 Years with Ulcerative Colitis - Video - November 26th, 2014 [November 26th, 2014]
- Mark: Healed of Ulcerative Colitis - Video - November 26th, 2014 [November 26th, 2014]
- Colonoscopy of Ulcerative Colitis - Video - November 30th, 2014 [November 30th, 2014]